What does the evidence show about Acarbose's effects?

Read Off Label rates the evidence for Acarbose as Moderate and the benefit magnitude as med, producing an overall grade of B- (6.3/10). ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings.

What safety findings are reported for Acarbose?

Acarbose has a low-med risk profile in the database. Low-Med (GI flatulence is common) Legal status: Rx (T2D); often OTC outside US.

Rankings / Longevity — Pharma (Off-Label)

Acarbose

Longevity · Alpha-glucosidase inhibitor

Also known as: Precose ·Glucobay

Tier B-

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

microbiomealpha-glucosidaseprescriptionotc

6.3 / 10

Tier B-

Ev 6 Bn 5 Sf 7

Bottom line

Read Off Label grades Acarbose as B- (6.3/10) based on moderate evidence, med benefit magnitude, and a low-med-risk safety profile.

ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings.

Studied, labeled, or reported-use context: 25-100 mg TID with first bite of meals — Rx (T2D); often OTC outside US; not individualized guidance.

What the evidence says

ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings. Human longevity data is extrapolated from diabetes trials and Japanese cohort data. Cheap and well-tolerated if GI side effects are acceptable.

Mechanism

Inhibits intestinal alpha-glucosidases; slows carbohydrate digestion; blunts postprandial glucose spike; produces more favorable microbiome (SCFA production)

Studied, labeled, or reported dose & route

25-100 mg TID with first bite of meals

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Acarbose's effects?: Read Off Label rates the evidence for Acarbose as Moderate and the benefit magnitude as med, producing an overall grade of B- (6.3/10). ITP: extended male mouse lifespan by 22%, female by 5% — one of the most robust ITP findings.
What safety findings are reported for Acarbose?: Acarbose has a low-med risk profile in the database. Low-Med (GI flatulence is common) Legal status: Rx (T2D); often OTC outside US.
What doses or routes are reported for Acarbose?: 25-100 mg TID with first bite of meals This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Acarbose work?: Inhibits intestinal alpha-glucosidases; slows carbohydrate digestion; blunts postprandial glucose spike; produces more favorable microbiome (SCFA production)

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.